Anderson, SCNCT07481981Now EnrollingIRB Ready

Pulmonary Arterial Hypertension Clinical Trial in Anderson, SC

Access cutting-edge pulmonary arterial hypertension treatment through this clinical trial at a research site in Anderson. Study-provided care at no cost to qualified participants.

Sponsored by Insmed Incorporated

Quick Self-Assessment

See if you qualify for this Anderson location

Preparing your pre-screening questions…

Expert Care in Anderson

Access pulmonary arterial hypertension specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pulmonary arterial hypertension treatment provided free

Apply for This Anderson Location

Check if you qualify for this pulmonary arterial hypertension clinical trial in Anderson, SC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Anderson

    Convenient for SC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Anderson site if eligible
  4. 4Begin participation

About This Pulmonary Arterial Hypertension Study in Anderson

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

Sponsor: Insmed Incorporated

Who Can Participate

Inclusion Criteria

Participants must have a diagnosis of World Health Organisation (WHO) Group 1 pulmonary hypertension (PAH) in any of the following subtypes, in accordance with European Society of Cardiology European Respiratory Society (ESC/ERS) Guidelines:
Idiopathic PAH
Heritable PAH
Drug/toxin-induced PAH
Connective tissue disease (CTD)-associated PAH
PAH associated with congenital heart disease-related to simple systemic-to-pulmonary shunt at least 1 year following repair.
PAH diagnosis for at least 3 months prior to Screening.
New York Heart Association (NYHA) or World Health Organization (WHO) functional class II-IV.
Participants must be on stable PAH therapy consisting of 1 to 3 medications from the following classes:
Endothelin receptor antagonists (eg, ambrisentan, bosentan, macitentan) for at least 90 days prior to Screening with the last 30 days on stable dose
Phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil) for at least 90 days prior to Screening with the last 30 days on stable dose
Guanylate cyclase stimulator (eg, riociguat) for at least 90 days prior to Screening with the last 30 days on stable dose
Activin signaling inhibitor (e.g., sotatercept) for at least 6 months prior to Screening, with the last 3 months on stable dose and meeting all the following conditions:
no active clinically significant bleeding (eg, epistaxis and gingival bleeding requiring medical interventions) within the past 3 months.
no history of major bleeding events or risks (eg, gastrointestinal or intracranial bleeding) within the past 6 months.
platelet counts ≥100,000 per microlitre (μL) at Screening
For both 6-minute walk tests (6MWTs), the values of 6-minute walk distance (6MWD) should be ≥ 150 and ≤ 450 meters at Screening.
Right heart catheterization (RHC) at Screening (or within 6 months prior to Screening, if available). Prior RHC may be used provided there has been no change in background PAH therapy and doses. The RHC must meet all of the following hemodynamic criteria:
Mean pulmonary arterial pressure (PAP) \>20 millimetre of mercury (mmHg) at rest.
pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤15 mmHg.
pulmonary vascular resistance (PVR) of ≥5 wood units (WU).

Exclusion Criteria

Diagnosis of PH WHO Groups 2, 3, 4, or 5, or subtypes of PH WHO Group 1 other than described in inclusion criterion 2 (eg, human immunodeficiency virus (HIV), complex congenital heart disease-associated PAH, portal hypertension-associated PAH, pulmonary veno-occlusive disease, Schistosomiasis associated PAH).
Clinically significant left heart disease, including left-sided valvular disease, left ventricular systolic or diastolic dysfunction, echocardiographic findings suggestive of post-capillary pulmonary hypertension, unstable ischemic heart disease, or unstable arrhythmias.
Evidence of airflow obstruction defined by forced expiratory volume in 1 second (FEV1) per forced vital capacity (FVC) \<0.7.
Evidence of significant restrictive lung disease as evidenced by FVC \<70% predicted normal.
Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism.
Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine).
Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease and/or may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial. Note: Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Anderson?

Yes, this clinical trial (NCT07481981) has an active research site in Anderson, SC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Arterial Hypertension Treatment Options in Anderson, SC

If you're searching for pulmonary arterial hypertension treatment options in Anderson, SC, this clinical trial (NCT07481981) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Anderson research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pulmonary arterial hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary arterial hypertension clinical trials near you to find additional studies recruiting in your area.

More Hypertension Trials in Anderson, SC

See all hypertension clinical trials recruiting in Anderson — not just this study.

Browse Hypertension Trials in Anderson →

Browse More Trials by Condition

Hypertension TrialsPulmonary Embolism TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Anderson?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Anderson, SC